{
  "id": 15780693,
  "title": "1 in 4 Army Men Have Low T; GLP-1 in Menopause; Retatrutide Side Effects on Reddit",
  "url": "https://urgent.news/2026/10/20/1-in-4-army-men-have-low-t-glp-1-in-menopause-retatrutide-side",
  "topic": "ai",
  "section": "AI",
  "published": "2026-10-20T17:50:37.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/endocrinology/generalendocrinology/123483"
  },
  "original_language": "en",
  "account": "Recent studies reveal concerning findings on the health of U.S. military personnel and the population at large. Approximately one in four active-duty Army men have low testosterone levels, defined as a single morning testosterone concentration below 300 ng/dL, according to a JAMA report. The CDC found that nearly half of American women aged 40 to 60 experience menopausal symptoms, with 15.6% of them using prescription medications to alleviate these issues, as reported in 2025. Additionally, one in six adults with type 1 diabetes reported moderate to severe depression or anxiety symptoms, as shown in data from the National Health Interview Survey. Researchers have discovered that GLP-1 receptor agonists and emerging multi-hormone receptor modulators can lead to greater weight loss and substantial reductions in blood pressure, as indicated by a meta-analysis of phase III trial data in eClinicalMedicine. Early research also hints at the potential anti-aging benefits of GLP-1 agonists, as suggested by CNN. Furthermore, Novo Nordisk's investigational combination of semaglutide and cagrilintide has shown promising results, with women in a phase III trial experiencing an average 25% weight loss, regardless of their menopausal stage, according to post-hoc analyses. Walmart has announced it will cover over 250 prescription drugs, including some insulins and GLP-1 drugs for diabetes, at no cost for its employees in 2027, as reported by CNBC. A Reddit analysis of users who have taken the unapproved weight-loss drug retatrutide revealed that the most frequently cited adverse events included increased appetite, fatigue, increased energy, insomnia, elevated heart rate, and muscle-related issues. Verdiva Bio recently discontinued a phase II study of a once-weekly oral GLP-1 drug candidate, citing market evolution, as mentioned in FierceBiotech. Additionally, Zealand Pharma and Generate Biomedicines have partnered to utilize artificial intelligence in the development of novel protein-based therapies for obesity and metabolic diseases.",
  "summary": "(MedPage Today) -- Roughly a quarter of active-duty U.S. Army men had a single morning testosterone concentration under 300 ng/dL, a commonly used cutoff for low testosterone. (JAMA) Nearly half of American women ages 40 to 60 reported menopausal...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}